Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.

Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA.

J Virol. 2010 Oct;84(19):9995-10003. doi: 10.1128/JVI.00505-10. Epub 2010 Jul 21.

2.

Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.

Ode H, Matsuyama S, Hata M, Hoshino T, Kakizawa J, Sugiura W.

J Med Chem. 2007 Apr 19;50(8):1768-77. Epub 2007 Mar 17.

PMID:
17367119
3.

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.

Gupta A, Jamal S, Goyal S, Jain R, Wahi D, Grover A.

BMC Bioinformatics. 2015;16 Suppl 19:S10. doi: 10.1186/1471-2105-16-S19-S10. Epub 2015 Dec 16.

4.

Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Liu X, Xiu Z, Hao C.

J Comput Aided Mol Des. 2009 May;23(5):261-72. doi: 10.1007/s10822-008-9256-x. Epub 2009 Feb 15.

PMID:
19219633
5.

Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.

Soares RO, Batista PR, Costa MG, Dardenne LE, Pascutti PG, Soares MA.

J Mol Graph Model. 2010 Sep;29(2):137-47. doi: 10.1016/j.jmgm.2010.05.007. Epub 2010 Jun 11.

PMID:
20541446
6.

Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.

Bihani SC, Das A, Prashar V, Ferrer JL, Hosur MV.

Biochem Biophys Res Commun. 2009 Nov 13;389(2):295-300. doi: 10.1016/j.bbrc.2009.08.138. Epub 2009 Aug 29.

PMID:
19720046
7.

Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

Kozísek M, Bray J, Rezácová P, Sasková K, Brynda J, Pokorná J, Mammano F, Rulísek L, Konvalinka J.

J Mol Biol. 2007 Dec 7;374(4):1005-16. Epub 2007 Oct 3.

PMID:
17977555
8.
9.

HIV-1 protease-substrate coevolution in nelfinavir resistance.

Kolli M, Ozen A, Kurt-Yilmaz N, Schiffer CA.

J Virol. 2014 Jul;88(13):7145-54. doi: 10.1128/JVI.00266-14. Epub 2014 Apr 9.

10.

Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.

Ode H, Ota M, Neya S, Hata M, Sugiura W, Hoshino T.

J Phys Chem B. 2005 Jan 13;109(1):565-74.

PMID:
16851048
11.

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA.

Antimicrob Agents Chemother. 2007 Feb;51(2):604-10. Epub 2006 Nov 20.

12.

Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.

Prashar V, Bihani SC, Ferrer JL, Hosur MV.

Chem Biol Drug Des. 2015 Sep;86(3):302-8. doi: 10.1111/cbdd.12494. Epub 2015 Jan 9.

PMID:
25487655
13.

Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Sasková KG, Kozísek M, Rezácová P, Brynda J, Yashina T, Kagan RM, Konvalinka J.

J Virol. 2009 Sep;83(17):8810-8. doi: 10.1128/JVI.00451-09. Epub 2009 Jun 17.

14.

Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.

Mittal S, Bandaranayake RM, King NM, Prabu-Jeyabalan M, Nalam MN, Nalivaika EA, Yilmaz NK, Schiffer CA.

J Virol. 2013 Apr;87(8):4176-84. doi: 10.1128/JVI.03486-12. Epub 2013 Jan 30.

15.

Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Lefebvre E, Schiffer CA.

AIDS Rev. 2008 Jul-Sep;10(3):131-42. Review.

16.
17.

Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.

Zhang Y, Chang YC, Louis JM, Wang YF, Harrison RW, Weber IT.

ACS Chem Biol. 2014 Jun 20;9(6):1351-8. doi: 10.1021/cb4008875. Epub 2014 Apr 28.

18.

Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.

Ragland DA, Nalivaika EA, Nalam MN, Prachanronarong KL, Cao H, Bandaranayake RM, Cai Y, Kurt-Yilmaz N, Schiffer CA.

J Am Chem Soc. 2014 Aug 27;136(34):11956-63. doi: 10.1021/ja504096m. Epub 2014 Aug 18.

19.

Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.

Cai Y, Schiffer C.

Methods Mol Biol. 2012;819:551-60. doi: 10.1007/978-1-61779-465-0_32.

20.

Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H.

J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28.

Supplemental Content

Support Center